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An editorial written by Fritz Stertz et al. in 2002 and pub-
ished in this journal was one of the ﬁrst to highlight concerns
bout the introduction of a new European Union (EU) clinical tri-
ls directive (Clinical Trials Directive 2001/20/EC) particularly for
esearch in emergency settings.1 The directive sought “to simplify
nd harmonize the administrative provisions governing clinical
rials in the European Community, by establishing a clear, trans-
arent procedure for conducting studies involving investigational
edicinal products”. It is widely acknowledged that the Directive
rought inunnecessary administrative and regulatoryburdens. The
nﬂexibility of the Directive led to individual countries creating
ocal legislation in an attempt to facilitate emergency research,
hich increasedvariationbetweencountries, andaddeddelays and
ncreased costs for researchers.2 A group of clinicians, ethicists and
awyers (the ‘Vienna Initiative to save European Research’ (VISEAR)
nvestigators) produced a consensus document to promote a uni-
ed approach to local legislation,3 although the recommendations
ere never fully implemented.
The EU announced its intent to revise the Clinical Trials Direc-
ive 2001/20/EC in July 2012.4 The consultation paper draws
peciﬁc attention to research in patients without capacity stat-
ng: “Regarding clinical trials in emergency situations, Directive
001/20/EC does so far not address the speciﬁc situation where,
ecause of the urgency of the situation, it is impossible to obtain
ree and informed consent from the subject or the legal repre-
entative (‘clinical trials in emergency situations’). To address this,
peciﬁc provisions on clinical trials in emergency situations have
een added in line with existing international guidance documents
n this issue.”
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ttp://dx.doi.org/10.1016/j.resuscitation.2013.01.018Article 32 addresses clinical trials in emergency settings. Para-
graph 1 sets out that informed consent may be obtained after the
start of the clinical trial provided that all of the following conditions
are fulﬁlled:
(a) due to the urgency of the situation, caused by a sudden life-
threatening or other sudden serious medical condition, it is
impossible to obtain prior informed consent from the subject
and it is impossible to supply prior information to the subject;
b) no legal representative is available;
(c) the subject has not previously expressed objections known to
the investigator;
d) the research relates directly to a medical condition which
causes the impossibility to obtain prior informed consent and
to supply prior information;
(e) the clinical trial poses a minimal risk to, and imposes a minimal
burden on, the subject.
The ERC welcomes revisions to the EU Directive that are
designed to facilitate research in emergencies whilst at the same
time safeguarding patients. However we express concerns about
the potential for misinterpretation of speciﬁc terminology. Specif-
ically paragraph 1, subsection (a), “due to the urgency of the
situation, caused by a sudden life-threatening or other sudden
serious medical condition”. Subjects may become incapacitated
either as a consequence of the underlying medical condition
or its treatment. For example, a subject with severe asthma
may require deep sedation to enable artiﬁcial ventilation to
prevent cardiac arrest. In this case, it is the treatment (i.e. seda-
tion), not the underlying condition that has rendered the subject
incapacitated.Sub-section (b), which demands that “no legal representative”
is present before the emergency research provision can be applied,
is problematic. First, even if a legal representative is present, there
is often uncertainty if he would have sufﬁcient mental capacity at
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he time of a relatives cardiac arrest to provide a considered view
f the patients wishes. Second, in emergencies, where immediate
reatment is time critical (e.g. in cardiac arrest), delays of even a
ew seconds in administering treatment substantially reduce the
hances of survival.5,6 Therefore, delaying treatment to obtain con-
ent would be harmful and, therefore, unethical.
Finally, subsection (d) requires that the research relates directly
o a medical condition which makes it impossible to obtain prior
nformed consent. Medical conditions leading to critical illness and
oss of capacity rarely occur in isolation. For example, if a subject
evelops acute renal failure as a consequence of cardiac arrest, the
enal failure per se is not the cause of the incapacity but research
nto the treatment of renal failure is important. Under the above
roposal there would be uncertainty about the legality of such
esearch.
The European Resuscitation Council has written formally to
he EU Standing Committee on Environment, Public Health and
ood Safety to express their concerns. We also encourage individ-
al researchers and national resuscitation councils to engage in
ialogue with their local regulators to highlight the potential for
isinterpretation and to seek clariﬁcation of wording before the
irective is ﬁnalized.
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